Find a Doctor

Dr. Tapan Mahendra Kadia

Physicians Referral Service
Oncology, Hematology, Internal Medicine
Practicing approx. 20 years

Bio


Tapan Kadia is an Internal Medicine specialist and an Oncologist in Houston, Texas. Dr. Kadia is a global expert in Prolymphocytic Leukemia. He has been an author on 287 peer reviewed articles and participated in 17 clinical trials in the past 15 years. In particular, he has been an author on 2 peer reviewed articles and participated in 2 clinical trials regarding Prolymphocytic Leukemia. He is licensed to treat patients in TX.

Contact

Houston, TX 77030, US

Latest Advances


  • Condition: Acute Myeloid Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Venetoclax with Decitabine versus Intensive Chemotherapy
  • Number of Patients: 170
  • Published —
The study compared the outcomes between venetoclax with decitabine versus intensive chemotherapy for treating acute myeloid leukemia.
  • Condition: Acute Myeloid Leukemia
  • Journal: Blood advances
  • Treatment Used: Cytarabine or Hypomethylating Agent-Based Regimen
  • Number of Patients: 202
  • Published —
This study evaluated the impact of TP53mut variant allelic frequency (variant allelic frequency) on clinical outcomes in patients with newly diagnosed acute myeloid leukemia.
  • Condition: Acute Myeloid Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: 10-day Decitabine with Venetoclax
  • Number of Patients: 168
  • Published —
The study researched the safety and effectiveness of 10-day decitabine with venetoclax for acute myeloid leukemia.
  • Condition: Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: Hyper-CVAD combined with Ofatumumab
  • Number of Patients: 69
  • Published —
This study tested the safety and efficacy of using hyper-CVAD combined with ofatumumab to treat patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
  • Condition: Leukemia in the Time of COVID-19
  • Journal: Acta haematologica
  • Treatment Used: Chemotherapy with or without Target Therapies
  • Number of Patients: 0
  • Published —
This article offers recommendations on the optimization of leukemia management during high-risk COVID-19 periods.
  • Condition: Older Patients with NPM1-Mutated Acute Myeloid Leukemia (AML)
  • Journal: Blood advances
  • Treatment Used: Standard Intensive Chemotherapy (IC) or Hypomethylating Agents (HMAs)
  • Number of Patients: 0
  • Published —
This study compared outcomes for patients with nucleophosmin-1 mutations (NPM1+) acute myeloid leukemia (AML) treated with treated with hypomethylating agents (HMA) plus BCL-2 inhibitor, venetoclax (VEN), hypomethylating agents, or intensive chemotherapy therapy.
  • Condition: Acute Lymphoblastic Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Liposomal Vincristine
  • Number of Patients: 31
  • Published —
In this study, researchers evaluated the outcomes of using liposomal vincristine in combination with intensive chemotherapy for the treatment of acute lymphoblastic leukemia.
  • Condition: Chronic-phase Chronic Myeloid Leukemia
  • Journal: Cancer
  • Treatment Used: Nilotinib
  • Number of Patients: 122
  • Published —
In this study, researchers evaluated the long term results of taking nilotinib 400 mg twice daily for the treatment of chronic-phase chronic myeloid leukemia.
  • Condition: Chronic Myeloid Leukemia
  • Journal: Cancer
  • Treatment Used: Dasatinib
  • Number of Patients: 149
  • Published —
This study evaluated the effectiveness of dasatinib to treat patients with chronic myeloid leukemia.
  • Condition: Acute Myeloid Leukemia (AML)
  • Journal: American journal of hematology
  • Treatment Used: Maintenance Therapy
  • Number of Patients: 0
  • Published —
This review summarizes previous and ongoing approaches of maintenance therapy in acute myeloid leukemia (AML) and discusses the most promising strategies.
  • Condition: Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
  • Journal: The Lancet. Haematology
  • Treatment Used: Idarubicin, Cytarabine, and Nivolumab
  • Number of Patients: 44
  • Published —
This study tested the safety and efficacy of using idarubicin, cytarabine, and nivolumab to treat patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
  • Condition: Newly Diagnosed, FLT3-Internal Tandem Duplication (ITD) Mutation-Positive Acute Myeloid Leukemia (AML)
  • Journal: Cancer
  • Treatment Used: Sorafenib plus Intensive Chemotherapy
  • Number of Patients: 183
  • Published —
This study investigated whether the addition of sorafenib to intensive induction chemotherapy improves outcomes in patients with FLT3-internal tandem duplication (ITD)-mutated acute myeloid leukemia (AML).
  • Condition: Acute Myeloid Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Intensive Chemotherapy with Sorafenib
  • Number of Patients: 183
  • Published —
This study investigated the changes in baseline FLT3-ITD mutant allele levels for patients with acute myeloid leukemia that were treated using intensive chemotherapy with sorafenib.
  • Condition: Acute Promyelocytic Leukemia (APL)
  • Journal: Cancer
  • Treatment Used: Induction Therapy
  • Number of Patients: 187
  • Published —
This study identified the risk factors associated with transfer to the intensive care unit (ICU) and endotracheal intubation during induction therapy in patients with acute promyelocytic leukemia (APL).
  • Condition: Chronic lymphocytic leukemia
  • Journal: The New England journal of medicine
  • Treatment Used: Ibrutinib and Venetoclax
  • Number of Patients: 80
  • Published —
The study aimed to determine the effects of using Ibrutinib and Venetoclax as a first-line treatment of chronic lymphocytic leukemia.
  • Condition: Older Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)
  • Journal: Cancer
  • Treatment Used: Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy (mini-HCVD) with or without Blinatumomab vs Standard Intensive Chemotherapy (HCVAD)
  • Number of Patients: 135
  • Published —
This study compared the effectiveness of inotuzumab ozogamicin combined with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) in older patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (cancer of a type of white blood cell called lymphocytes; ALL).
  • Condition: Chronic myeloid leukemia
  • Journal: Blood advances
  • Treatment Used: Tyrosine kinase inhibitors
  • Number of Patients: 531
  • Published —
The study researched the side effects of patients with chronic myeloid leukemia being treated with tyrosine kinase inhibitors.
  • Condition: RAS-Mutant Acute Myeloid Leukemia (AML)
  • Journal: Clinical lymphoma, myeloma & leukemia
  • Treatment Used: MEK Inhibitor Binimetinib (MEK162)
  • Number of Patients: 19
  • Published —
This study evaluate the safety and effectiveness of the MEK 1/2 inhibitor binimetinib in patients with advanced myeloid malignancies.
  • Condition: Older Patients With Newly Diagnosed Acute Myeloid Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: 5-day versus 10-day schedule of decitabine
  • Number of Patients: 71
  • Published —
The purpose of the study was to assess outcomes in older patients with newly diagnosed acute myeloid leukemia who received a 5-day schedule versus a 10-day schedule of decitabine.
  • Condition: Chronic Lymphocytic Leukemia
  • Journal: Blood
  • Treatment Used: Ibrutinib vs. Ibrutinib plus Rituximab
  • Number of Patients: 208
  • Published —
This study compared ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
  • Condition: Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)
  • Journal: Cancer
  • Treatment Used: Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab
  • Number of Patients: 48
  • Published —
This study evaluated the outcomes of chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in first salvage.
  • Condition: Myelofibrosis
  • Journal: Blood
  • Treatment Used: ruxolitinib in combination with azacitidine
  • Number of Patients: 46
  • Published —
This study aim to evaluate ruxolitinib in combination with azacitidine in patients with myelofibrosis.
  • Condition: Elderly Patients With Acute Myeloid Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: Cladribine and low-dose cytarabine alternating with decitabine
  • Number of Patients: 118
  • Published —
The purpose of the study was to determine the safety and efficacy of Cladribine and low-dose cytarabine alternating with decitabine in treating elderly patients with acute myeloid leukemia.
  • Condition: Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Sorafenib and 5-azacytidine
  • Number of Patients: 27
  • Published —
The study compared the combination of Sorafenib and 5-azacytidine in treating older patients with untreated FLT3-ITD mutated acute myeloid leukemia.
  • Condition: Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
  • Journal: The Lancet. Oncology
  • Treatment Used: Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy
  • Number of Patients: 52
  • Published —
This study assessed the activity and safety of inotuzumab ozogamicin in combination with low-intensity chemotherapy in older patients with acute lymphoblastic leukemia.
  • Condition: Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  • Journal: American journal of hematology
  • Treatment Used: Ruxolitinib with Azacytidine
  • Number of Patients: 35
  • Published —
This study evaluated ruxolitinib and azacytidine in the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs).

Clinical Trials


Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 62
  • Start Date: December 31, 2020
Phase Ib Study of Fludarabine, Cytarabine (Ara-C) and Pegylated Erwinase (Pegcrisantaspase) in Patients With Relapsed or Refractory Leukemia
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 69
  • Start Date: December 4, 2020
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug, Biological
  • Participants: 15
  • Start Date: January 15, 2020
Phase Ib Pilot Study of Itacitinib With Alemtuzumab in Patients With T-Cell Prolymphocytic Leukemia (T-PLL)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 50
  • Start Date: September 13, 2019
Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With High Risk AML in Remission
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 18
  • Start Date: May 30, 2019
Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Other, Drug
  • Participants: 72
  • Start Date: January 31, 2019
Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 52
  • Start Date: October 29, 2018
Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 54
  • Start Date: July 25, 2017
Phase I Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory Leukemias
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 20
  • Start Date: December 2, 2016
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Biological, Other
  • Participants: 30
  • Start Date: October 19, 2015
PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Other, Drug
  • Participants: 50
  • Start Date: November 13, 2014
Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Other
  • Participants: 408
  • Start Date: May 19, 2014
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
Clinical Trial
  • Status: Unknown status
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 65
  • Start Date: June 17, 2010
A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes

Contact

Houston, TX 77030, US

Affiliations

  • The University Of Texas M.d. Anderson Cancer Center

Credentials

  • Graduate InstitutionRutgers R W Johnson Medical School (Cam/new Bruns/pisc)
    2001
  • Licenses
    Internal Medicine in TX
  • Board Certifications
    Internal Medicine
    Hematology
    Medical Oncology

Insurance

Contact them to find out if they accept your insurance plan.